Pd04-09 Efficacy and Safety of Mirabegron Compared to Solifenacin in Treatment of Non-Neurogenic Voiding Dysfunction in Children: A Randomized Controlled Trial

You have accessJournal of UrologyPediatrics I (PD04)1 May 2024PD04-09 EFFICACY AND SAFETY OF MIRABEGRON COMPARED TO SOLIFENACIN IN TREATMENT OF NON-NEUROGENIC VOIDING DYSFUNCTION IN CHILDREN: A RANDOMIZED CONTROLLED TRIAL Islam R. Mansour, Ahmed El-hefnawy, Ahmed Abd Elhalim, Mahmoud Laymon, and Mohamed Dawaba Islam R. MansourIslam R. Mansour , Ahmed El-hefnawyAhmed El-hefnawy , Ahmed Abd ElhalimAhmed Abd Elhalim , Mahmoud LaymonMahmoud Laymon , and Mohamed DawabaMohamed Dawaba View All Author Informationhttps://doi.org/10.1097/01.JU.0001008812.05762.7f.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Non-neurogenic voiding dysfunction is a common problem in pediatric population. It affects 17-22% of children above the age of 5 years. Antimuscarinic drugs have been widely used as first line medical treatment. The predominant side effects of antimuscarinic drugs necessitated the use of alternative new medications, namely Beta 3 agonists as Mirabegron. We aimed to assess efficacy and safety of Mirabegron in treatment of children with non-neuogenic voiding dysfunction compared to the standard antimuscarinics as Solifenacin. METHODS: A Prospective randomized controlled trial was conducted between February 2022 and January 2023 on 84 children with non-neurogenic voiding dysfunction not responding to behavioral therapy. Patients were randomized into 2 groups which received Mirabegron and Solifneacin respectively. Patients were primarily assessed using dysfunctional voiding scoring system questionnaire (DVSS) at the beginning and end of the study, in addition to 3-day voiding diary and uroflowmetry. Vital signs and adverse effects were specifically recorded. RESULTS: A total of 72 patients completed the study with a mean age of (9.2±2.3) years. Both groups showed significant improvement in DVSS questionnaire and voiding diary compared with baseline data (p<0.001). However, Mirabegron group showed better efficacy than Solifenacin at the end of the study. Improvement≥50% of the score of the DVSS questionnaire was achieved in 34 of 36 (94%) patients on Mirabegron versus 27 of 36 (75%) on Solifenacin (p=0.02). Complete improvement down to a score of zero was observed in 8 of 36 (22%) patients on Mirabegron versus 3 of 36 (8%) on Solifenacin (p=0.1%). Moreover, Mirabegron group had significantly better safety profile. Side effects were reported in 7 of 36 (19.4%) of Mirabegron group compared to 17 of 36 (47.2%) of Solifenacin (p=0.01). CONCLUSIONS: Mirabegron appears to be more effective than Solifenacin in management of children with non-neurogenic voiding dysfunction as a complex problem comprising a wide range of storage and voiding LUTS, in addition to interrelated bowel dysfunction. It is also more safe and tolerable especially in children who are expected to be subjected to medical treatment for long duration. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e86 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Islam R. Mansour More articles by this author Ahmed El-hefnawy More articles by this author Ahmed Abd Elhalim More articles by this author Mahmoud Laymon More articles by this author Mohamed Dawaba More articles by this author Expand All Advertisement PDF downloadLoading ...